Two Cases of Human Papillomavirus-Related Oropharyngeal Cancer After the Treatment of Cervical Cancer

Tomoko Yamazaki

1. Head and Neck Cancer: Medical Oncology, Miyagi Cancer Center, Natori, JPN

Corresponding author: Tomoko Yamazaki, tomoko-yamazaki@miyagi-pho.jp

Abstract

Recently, the incidence of human papillomavirus (HPV)-related head and neck cancers (oropharynx and oral) has increased rapidly. Secondary HPV-related cancers after an initial index cancer at a site associated with an HPV infection have been reported, including invasive cervical, vaginal, vulval, anal, penile, and oropharyngeal cancer.

Here, we describe two female oropharyngeal cancer patients who had been treated for secondary cervical cancers with chemoradiotherapy and achieved a good clinical response.

Categories: Otolaryngology, Oncology

Keywords: hpv-related oropharyngeal cancer, cervical cancer, double cancer, human papillomavirus

Introduction

The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has recently increased worldwide [1]. Patients with HPV-related OPC tend to be younger and have lower rates of tobacco and alcohol use than patients with HPV-unrelated OPC. The prognosis for HPV-related OPC is better than that for HPV-unrelated disease [1-2]. The latest Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) ver. 8 tumor, node, metastasis (TNM) staging of OPC thus distinguished between HPV-related and HPV-unrelated OPC [3-4].

According to the World Health Organization (WHO), HPV is now the most common sexually transmitted infection worldwide, with approximately 5% of all cancers being caused by HPV [5-6]. Although patients diagnosed with primary HPV-related cancers are often cured, they remain at risk for secondary HPV-related malignancies, necessitating the careful follow-up of these patients [7].

Case Presentation

Case 1

A 69-year-old female with HPV-related OPC was referred to our hospital in December 2016. She had suffered from HPV type 16-related cervical cancer at age 58 years and was treated with surgery followed by adjuvant chemoradiotherapy. She had had no recurrence. She was neither a smoker nor a drinker. She felt painless cervical lymph nodes on the right side in August 2016 and visited a local otolaryngologist in December 2016. Fiberoptic laryngoscopy revealed a tumor extending from the tonsil to the soft palate on the right (Figure 1). Biopsy of the oropharyngeal lesion confirmed well-differentiated squamous cell carcinoma of the right soft
A magnetic resonance imaging (MRI) scan confirmed a primary lesion of approximately 3 cm extending from the right tonsil to the soft palate on the right with bilateral enlarged cervical and retropharyngeal lymph nodes, from levels II to IV and Vb. Their maximum diameter was approximately 2 cm. There was no evidence of extranodal infiltration (Figure 2). Computed tomography (CT) of the chest, abdomen, and pelvis revealed no abnormalities.

FIGURE 1: Case 1; The primary site of fiberscopic laryngoscopy

A tumor extending from the tonsil to the soft palate on the right side
She was staged as clinical T2N2cM0 (stage IVA, AJCC 7th edition 2010, Stage II, AJCC 8th edition 2018, HPV IHC[+], p16/INK4a gene expression [++] , type 16 positive and type 18 positive). At the tumor board meeting, it was decided that she should receive cisplatin (CDDP)-based chemoradiotherapy (CRT). Following the placement of percutaneous endoscopic gastrostomy (PEG), CRT (intensity-modulated radiation therapy (IMRT) 70 Gy/35 fractions and CDDP 80 mg/m² for two cycles) were initiated in February 2017. As she developed Grade 3 neutropenia and leukopenia, chemotherapy was delayed, but she was able to complete radiation therapy without radiation interruption. Radiation dermatitis was Grade 2 and mucositis was Grade 3. After the treatment was completed, she required tube feeding via PEG. Following rehabilitation, she could eat orally after two months. She achieved a complete response and has remained alive since then.

Case 2

A 70-year-old female with HPV-related OPC was referred to our hospital in December 2018. She
had suffered from cervical cancer at 36 years of age and was treated successfully with surgery. The HPV type was unknown because the operation was performed 34 years ago. She was neither a smoker nor a drinker. She noted painless neck nodes on the left and visited a local otolaryngologist in December 2018. Fiberoptic laryngoscopy revealed reddish discoloration on the left tonsil (Figure 3). Biopsy of the lesion confirmed well-differentiated squamous cell carcinoma of the left tonsil.

![Image of tonsil](image)

**FIGURE 3: Case 2; the primary site of the fiberoptic laryngoscopy**

Reddish discoloration on the left tonsil

Findings on the magnetic resonance imaging (MRI) scan were of the primary tonsillar lesion measuring approximately 3 cm. The lymphadenopathy was defined as level III on the left side. The maximum lymph node diameter was approximately 3 cm; there was no extranodal infiltration (Figure 4). She was staged as clinical T2N1M0 (Stage I, AJCC 8th edition 2018), HPV IHC [+], p16/INK4a gene expression [++] , type 16 positive, and type 18 negative.
She received PEG and underwent CRT in January 2019. IMRT was 70 Gy/35 fractions and CDDP 80 mg/m$^2$ for three cycles. The treatment was completed with only one adverse event, Grade 3 mucositis, requiring tube feeding via PEG. Following rehabilitation, she could eat orally after two months. She achieved a complete response, has had no recurrence, and remains alive at nine months after treatment.

**Discussion**

Here, we present two patients with remote histories of successfully treated cervical cancer who presented with new-onset HPV-positive OPC.

Approximately 5% of all cancers worldwide are caused by HPV, including 90%-93% of anal cancers, 12%-63% of OPCs, 36%-40% of penile cancers, 40%-60% of vaginal cancers, and 40%-51% of vulvar cancers [7-8]. The incidence of HPV-related OPC has risen rapidly in recent years [9-10]. According to repository data from the Surveillance, Epidemiology, and End Results
(SEER) program, the prevalence of HPV-negative cancers decreased by 50% from 1988 to 2004, while that of HPV-positive OPC increased by 225%[11]. HPV-related OPC patients have a better prognosis than those with HPV-unrelated disease. HPV-related OPC patients also tend to be younger and healthier, with a higher income and no history of tobacco or alcohol abuse [12-13]. In comparison, patients with HPV-unrelated OPC tend to be heavy smokers and drinkers.

However, if healthy, young, nonsmoking patients with symptoms such as painlessly enlarged neck lymph nodes fail to seek medical attention, the appropriate diagnosis and treatment will be delayed. Psychological distress is also reportedly more frequent among patients with HPV-related than those with HPV-unrelated OPC, while head and neck cancers are associated with the highest levels of distress among oncology patients, with high incidences of major depression and anxiety [5,14-15]. Head and neck cancer survivors are almost twice as likely to die from suicide than survivors of other cancers, indicating the need to include mental health professionals in multidisciplinary teams involved in the care of patients with head and neck cancer. In addition, all patients with head and neck cancer require surveillance for possible recurrence and secondary primary cancers. Given that patients with HPV-related OPC tend to be younger, they require particular support and meticulous care.

The seventh edition of the AJCC/UICC TNM staging system did not consistently distinguish between prognostic subgroups for HPV-related and non-HPV-related OPC. However, the eighth edition, which does subclassify according to HPV status, came into effect on or after January 1, 2017 [3-4].

HPV immunostaining is now required in patients with OPC. Although it does not detect HPV directly, p16 is considered a surrogate marker, and p16 immunohistochemistry is economical and convenient, with high sensitivity [16].

HPV-associated-cervical cancer is classified into high-risk and low-risk groups, among which HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are considered high risk [17]. HPV infection is very common and women who acquire the virus sexually remain infected throughout their lives. About 70% of newly acquired HPV infections disappear within one year and about 90% within two years [18]. However, HPV infection for >12 continuous months increases the risk of cervical cancer.

A meta-analysis found that patients with any HPV-related first primary cancer were at an increased risk of developing a second primary cancer such as cervical cancer. A second primary cancer may involve the same or a different area as the primary cancer [19].

We considered if HPV-related OPC was caused by the same HPV types as cervical cancer. Case 1 received diagnoses of both types of cancer. However, although Case 2 had OPC caused by HPV 16, she had been treated for cervical cancer 34 years ago at another hospital and the samples were unavailable.

There is currently no routine examination system for head and neck cancer in Japan. Most patients visit a local doctor when they have symptoms such as neck lymph node swelling, pain, and difficulty swallowing and are only referred to institutions such as ours when their conditions have already worsened. Recent studies suggested that vaccination may protect against oral HPV infection, and vaccinated adults had a lower prevalence of HPV infection in both the oral cavity and other areas as compared with unvaccinated adults [20]. We, therefore, suggest that all children should receive HPV vaccination in Japan.

Conclusions
In conclusion, HPV-related cancer (for example, cervical, anal, vaginal, and so on) patients should be examined regularly, for a long time. In addition, we have to impart correct information about HPV and HPV vaccination.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Ang KK, Harris J, Wheeler R, et al.: Human papillomavirus and survival of patients with oropharyngeal cancer. New Eng J Med. 2010, 363:24-35. 10.1056/NEJMoa0912217
2. O’Sullivan B, Huang SH, Siu LL, et al.: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013, 31:545-550. 10.1200/jco.2012.44.0164
3. Panwar A, Interval E, Lydiatt WM: Emergence of a novel staging system for oropharyngeal squamous cell carcinoma based on HPV status. Oncology. 2017, 31:53-40.
4. Amin MB, Greene FL, Edge SB, et al.: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017, 67:93-99. 10.3322/caac.21388
5. You EL, Henry M, Zeitouni AG: Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management. Curr Oncol. 2019, 26:119-123. 10.3747/co.26.4819
6. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM: Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020, 8:180-190. 10.1016/S2214-109X(19)30488-7
7. Gilbert DC, Wakeham K, Langley RE, Vale CL: Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. Br J Cancer. 2019, 120:256-268. 10.1038/s41416-018-0273-9
8. Chaturvedi AK, Graubard BI, Brounian T, et al.: Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018, 36:262-267. 10.1200/jco.2017.75.0141
9. Guo T, Eisele DW, Fakhry C: The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer. 2016, 122:2513-2523. 10.1002/cncr.29992
10. Hama T, Tokumaru Y, Fujii M, et al.: Prevalence of human papillomavirus in oropharyngeal cancer: a multicenter study in Japan. Oncology. 2014, 87:173-182. 10.1159/000350991
11. Pytynia KB, Dahlstrom KR, Sturgis EM: Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014, 50:580-586. 10.1016/j.oraloncology.2013.12.019
12. O’Sullivan B, Huang SH, Perez-Ordonez B, et al.: Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol. 2012, 103:49-56. 10.1016/j.radonc.2012.02.009
13. Horne ZD, Glaser SM, Vargo JA, et al.: Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. Cancer. 2016, 122:2021-2030. 10.1002/cncr.30021
14. Kam D, Salib A, Gorgy G, et al.: Incidence of suicide in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2015, 141:1075-1081. 10.1001/jamaoto.2015.2480
15. Henry M, Rosberger Z, Bertrand L, et al.: Prevalence and risk factors of suicidal ideation among patients with head and neck cancer: longitudinal study. Otolaryngol Head Neck Surg.
16. El-Naggar AK, Westra WH: p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012, 34:459-461. 10.1002/hed.21974

17. Munoz N, Bosch FX, de Sanjose S, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Eng J Med. 2003, 348:518-527. 10.1056/NEJMoa021641

18. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. New Eng J Med. 1998, 338:423-428. 10.1056/NEJM199802123380703

19. Ryan S, Parag M, Kalyani S, et al.: Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open. 2018, 1:e181999. 10.1001/jamanetworkopen.2018.1999

20. Tumban E: A current update on human papillomavirus-associated head and neck cancers. Viruses. 2019, 11:922. 10.3390/v11100922